Evidence map›Paper›PMID 38268026›Full record

ArticleBiology direct2024

Effect of glycosylation on the affinity of the MTB protein Ag85B for specific antibodies: towards the design of a dual-acting vaccine against tuberculosis.

Roberta Bernardini, Sara Tengattini, Zhihao Li, Luciano Piubelli, Teodora Bavaro, Anamaria Bianca Modolea, Maurizio Mattei, Paola Conti, Stefano Marini, Yongmin Zhang and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biology direct, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Antigen 85B ofVaccines · 2026
    Review
  2. Article
  3. GCI-Based Affinity Screening of Synthetic Oligomannosides toward Concanavalin A.Chemistry (Weinheim an der Bergstrasse, Germany) · 2025
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

Roberta Bernardini *Department of Translational Medicine, University of Tor Vergata, Via Montpellier 1, Rome, 00133, Italy. roberta.bernardini@uniroma2.it.
Sara Tengattini *Drug Sciences Department, University of Pavia, Viale Taramelli 12, Pavia, 27100, Italy. sara.tengattini@unipv.it.
Zhihao LiParisian Institute of Molecular Chemistry, Sorbonne University, UMR CNRS 8232, 4 Place Jussieu, Paris, 75005, France.
Luciano PiubelliDepartment of Biotechnology and Life Sciences, University of Insubria, via J.H. Dunant, 3, Insubria, Varese, 21100, Italy.
Teodora BavaroDrug Sciences Department, University of Pavia, Viale Taramelli 12, Pavia, 27100, Italy.
Anamaria Bianca ModoleaInterdepartmental Center for Comparative Medicine, Alternative Techniques and Aquaculture (CIMETA), University of Rome "Tor Vergata", Via Montpellier 1, Rome, 00133, Italy.
Maurizio MatteiInterdepartmental Center for Comparative Medicine, Alternative Techniques and Aquaculture (CIMETA), University of Rome "Tor Vergata", Via Montpellier 1, Rome, 00133, Italy.
Paola ContiDepartment of Pharmaceutical Sciences, University of Milan, Via Mangiagalli 25, Milan, 20133, Italy.
Stefano MariniDepartment of Translational Medicine, University of Tor Vergata, Via Montpellier 1, Rome, 00133, Italy.
Yongmin ZhangParisian Institute of Molecular Chemistry, Sorbonne University, UMR CNRS 8232, 4 Place Jussieu, Paris, 75005, France.
Loredano PollegioniDepartment of Biotechnology and Life Sciences, University of Insubria, via J.H. Dunant, 3, Insubria, Varese, 21100, Italy.
Caterina TemporiniDrug Sciences Department, University of Pavia, Viale Taramelli 12, Pavia, 27100, Italy.
Marco TerreniDrug Sciences Department, University of Pavia, Viale Taramelli 12, Pavia, 27100, Italy.
University of Pavia · ITUniversity of Rome Tor Vergata · ITCentre National de la Recherche Scientifique · FRUniversity of Insubria · ITUniversity of Milan · IT

Funding

Italian Ministry of Health (Traiettoria4 - Immunoterapia: cura e prevenzione di malattie infettive e tumorali - Immuno-HUB) T4-CN-02
6 · The paper itself

Abstract

backgroundTo create a dual-acting vaccine that can fight against tuberculosis, we combined antigenic arabino-mannan analogues with the Ag85B protein. To start the process, we studied the impact of modifying different parts of the Ag85B protein on its ability to be recognized by antibodies.

resultsThrough our research, we discovered that three modified versions of the protein, rAg85B-K30R, rAg85B-K282R, and rAg85B-K30R/K282R, retained their antibody reactivity in healthy individuals and those with tuberculosis. To further test the specificity of the sugar AraMan for AraMan antibodies, we used Human Serum Albumin glycosylated with AraMan-IME and Ara

conclusionsCoupling Ara

Indexed as

TuberculosisVaccinesGlycosylationHumansSugarsSugarsVaccinesAntibodiesGlycoconjugateImmune responseLipoarabinomannanMycobacteriumTuberculosisVaccine

Identifiers

PMID38268026
PMCPMC10809592
OpenAlexW4391227159

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.